Finch Therapeutics Revenue vs. Cash Per Share
Based on Finch Therapeutics' profitability indicators, Finch Therapeutics Group may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Finch Therapeutics' ability to earn profits and add value for shareholders.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Please note, there is a significant difference between Finch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Finch Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Finch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For Finch Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Finch Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Finch Therapeutics Group utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Finch Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Finch Therapeutics Group over time as well as its relative position and ranking within its peers.
Finch |
Finch Therapeutics Cash Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Finch Therapeutics's current stock value. Our valuation model uses many indicators to compare Finch Therapeutics value to that of its competitors to determine the firm's financial worth. Finch Therapeutics Group is rated below average in revenue category among its peers. It is rated below average in cash per share category among its peers . The ratio of Revenue to Cash Per Share for Finch Therapeutics Group is about 48,858 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Finch Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Finch Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Finch Revenue vs. Competition
Finch Therapeutics Group is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 57.33 Million. Finch Therapeutics adds roughly 107,000 in revenue claiming only tiny portion of equities under Health Care industry.
Finch Cash Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Finch Therapeutics |
| = | 107 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Finch Therapeutics |
| = | 2.19 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Finch Cash Per Share Comparison
Finch Therapeutics is currently under evaluation in cash per share category among its peers.
Finch Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Finch Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Finch Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Finch Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Finch Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.
Finch Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Finch Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Finch Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Finch Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Finch Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Use Investing Themes to Complement your Finch Therapeutics position
In addition to having Finch Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Non-Metallic and Industrial Metal Mining Thematic Idea Now
Non-Metallic and Industrial Metal Mining
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Non-Metallic and Industrial Metal Mining theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Non-Metallic and Industrial Metal Mining Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |